Quantification of diphosphonate uptake based on conventional bone scanning

European Journal of Nuclear Medicine

Volumn 24, Issue 10, 1997, Pages 1284-1290

  Brenner, Winfried ^a   Bohuslavizki, Karl Heinz ^a   Sieweke, Nicole ^a   Tinnemeyer, Stephan ^a   Clausen, Malte ^b   Henze, Eberhard ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bone scanning; Diphosphonate; Metabolic bone disease; Quantitative bone uptake measurement

Indexed keywords

ETIDRONIC ACID TC 99M;

ADULT; AGED; ARTICLE; BONE; BONE SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG EXCRETION; DRUG TISSUE LEVEL; DRUG UPTAKE; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; METABOLIC BONE DISEASE; SOFT TISSUE;

ADULT; AGED; BONE AND BONES; BONE DISEASES, METABOLIC; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE; TISSUE DISTRIBUTION;

EID: 0030693238     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050153     Document Type: Article

References (24)

1. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR. The use of whole body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 1978; 19: 270-275.
2. Holmes RA. Quantification of skeletal Tc-99m labeled phosphates to detect metabolic bone disease. J Nucl Med 1978 19: 330-331.
3. Caniggia A, Vattimo A. Kinetics of 99m technetium-tin-methylene diphosphonate in normal subjects and pathological conditions: a simple index of bone metabolism. Calcif Tissue Int 1980; 30: 5-13.
4. Fogelman I, Bessent RG, Beastall G, Boyle IT. Estimation of skeletal involvement in primary hyperparathyroidism. Use of 24-hour whole body retention of technetium-99m diphosphonate. Ann Intern Med 1980; 92: 65-67.
5. Fogelman I. Bone scanning. In: Maisey MN, Britton KE, Gilday DL, eds. Clinical nuclear medicine. London: Chapman Hall; 1991: 131-157.
6. Martin W, Fogelman I, Bessent RG. Measurement of 24-hour whole-body retention of Tc-99m HEDP by a gamma camera. J Nucl Med 1981; 22: 542-545.
7. Thomsen K, Johansen J, Nilas L, Christiansen C. Whole body retention of Tc-99m-diphosphonate. Relation to biochemical indices of bone turnover and to total body calcium. Eur J Nucl Med 1987; 13: 32-35.
8. Rosenthall L, Arzoumanian A. Total body retention measurements of Tc-99m MDP using a simple detector. Clin Nucl Med 1983; 8: 210-213.
9. Nisbet AP, Edwards S, Lazarus CR, Pharm B, Malamitsi J, Maisey MN, Winn PJ. Chromium 51 EDTA/technetium 99m MDP plasma ratio to measure total skeletal function. Br J Radiol 1984; 57: 677-680.
10. Smith ML, Martin W, Fogelman I, Bessent RG. Relative distribution of diphosphonate between bone and soft tissue at 4 and 24 hours: concise communication. J Nucl Med 1983; 24: 208-211.
11. Waxman AD, Ducker S, McKee D, Siemsen JK, Singer FR. Evaluation of Tc-99m diphosphonate kinetics and bone scans in patients with Paget's disease before and after calcitonin treatment. Radiology 1977; 125: 761-764.
12. D'Addabbo A, Rubini G, Mele M, Lauriero F. A new method for assessing Tc-99m-MDP bone uptake from a bone scan image: quantitative measurement of radioactivity in global skeletal region of interest. Nucl Med Commun 1992; 13: 55-60.
13. Hyldstrup L, Mogensen N, Jensen GF, McNair P, Transbol I. Urinary Tc-99m-diphosphonate excretion as a simple method to quantify hone metabolism. Scand J Clin Lab Invest 1984; 44: 105-109.
14. Thomson K, Gotfredsen A, Christiansen C. Bone turnover in healthy adults measured by whole body retention and urinary excretion of Tc-99m-MDP. Normalization by bone mass. Scand Clin Lab Invest 1986; 46: 587-592.
15. Marienhagen J, Männer P, Bock E, Schönberger J, Eilles C. Quantitative whole body scintigraphy - a simplified approach. Nuklearmedizin 1996; 35: 20-24.
16. Sachs L. Applied statistics. A handbook of techniques. Berlin Heidelberg New York: Springer, 1984.
17. Smith ML. Quantitative Tc-99m diphosphonate uptake measurements. In: Fogelman I, ed. Bone scanning in clinical practice. London Berlin Heidelberg New York: Springer: 1987: 237-248.
18. Rubini G, Lauriero F, Rubini D, D'Addabbo A. Tc-99m-MDP global skeletal uptake and markers of bone metabolism in patients with bone disease. Nucl Med Commun 1993; 14: 567-572.
19. Carnevale V, Frusciante V, Scillitani A, Modoni S, Pileri M, Chiodini I, Dicembrino F, Romagnoli E, Minisola S. Age-related changes in the global skeletal uptake of technetium-99m methylene diphosphonate in healthy women. Eur J Nucl Med 1996; 23: 1473-1477.
20. Fogelman I, Pearson DW, Bessent RG, Tote AJ, Francis MD. A comparison of skeletal uptake of three diphosphonates by whole-body retention. J Nucl Med 1981; 22: 880-883.
21. Fogelman I. Tc-99m diphosphonate bone scanning agents. In: Fogelman I, ed. Bone scanning in clinical practice. London Berlin Heidelberg New York: Springer; 1987: 31-40.
22. Citrin DL, Bessern RG, McGinlay E, Gordon D. Dynamic studies with Tc-99m HEDP in normal subjects and in patients with bone tumours. J Nucl Med 1975; 16: 886-890.
23. Fogelman I, Citrin DL, McKillop JH, Turner JG, Bessent RG, Greig WR. A clinical comparison of Tc-99m HEDP and Tc-99m MDP in the detection of bone metastases: concise communication. J Nucl Med 1979; 20: 98-101.
24. Makler PT, Charkes ND. Studies of skeletal tracer kinetics. IV. Optimum time delay for Tc-99m (Sn) methylene diphosphonate bone imaging. J Nucl Med 1980; 21: 641-645.